SIAP
DNTH icon

Sterling Investment Advisors (Pennsylvania)’s Dianthus Therapeutics DNTH Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-125
Closed -$6K – 571
2022
Q1 		$6K Hold
125
– – ﹤0.01% 480
2021
Q4 		$9K Hold
125
– – ﹤0.01% 446
2021
Q3 		$15K Hold
125
– – ﹤0.01% 397
2021
Q2 		$20K Buy
+125
New +$23K 0.01% 353

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s DNTH Position: Q2 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 125 shares — an estimated $6K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in DNTH in Q2 2021 and held it in 4 quarters. The position peaked at $20K in Q2 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 125 Dianthus Therapeutics shares in Q2 2022, an estimated $6K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Dianthus Therapeutics in Q2 2021 and held it in 4 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Dianthus Therapeutics position peaked at $20K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q2 2022, filed 5 Aug 2022.